Generic Nexiclon XR Availability
Last updated on Apr 10, 2024.
Nexiclon XR is a brand name of clonidine, approved by the FDA in the following formulation(s):
NEXICLON XR (clonidine - tablet, extended release;oral)
-
Manufacturer: ATHENA
Approval date: December 3, 2009
Strength(s): EQ 0.17MG BASE, EQ 0.26MG BASE (discontinued)
Has a generic version of Nexiclon XR been approved?
An Authorized Generic version of Nexiclon XR has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance and has exactly the same inactive ingredients.
List of authorized generic versions:
- Clonidine ORAL TABLET, EXTENDED RELEASE .17 mg
TruPharma, LLC
NDC Code: 528170375 - Clonidine ORAL TABLET, EXTENDED RELEASE .17 mg
PALMETTO PHARMACEUTICALS INC.
NDC Code: 681340603
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nexiclon XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Modified release formulations containing drug-ion exchange resin complexes
Patent 8,337,890
Issued: December 25, 2012
Inventor(s): Mehta Ketan & Tu Yu-Hsing
Assignee(s): Tris Pharma IncA coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.
Patent expiration dates:
- April 17, 2027✓
- April 17, 2027
-
Clonidine formulation
Patent 8,623,409
Issued: January 7, 2014
Inventor(s): Mehta Ketan & Tu Yu-Hsing
Assignee(s): Tris Pharma Inc.An oral clonidine dosage unit providing a twenty-four hour extended release profile following a single dose administration is provided. The dosage unit comprises a pharmaceutically effective amount of a coated complex comprising clonidine bound to a cationic exchange resin, which is characterized by a twenty-four hour release profile with a single peak, wherein said oral clonidine dosage unit provides a therapeutically effective plasma concentration for at least about 70%, or at least 85% of the twenty-four hour period following the single dose administration. Both liquid and solid formulations are provided, as are methods of treating a patient by a single administration of a formulation of the invention so as to achieve a therapeutic effect for 24-hours.
Patent expiration dates:
- September 8, 2031✓
- September 8, 2031
More about Nexiclon XR (clonidine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- Drug class: antiadrenergic agents, centrally acting
- Breastfeeding
Patient resources
Other brands
Catapres, Catapres-TTS, Kapvay, Duraclon
Professional resources
Other brands
Catapres, Catapres-TTS, Kapvay, Duraclon
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
